Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
Medicamen Biotech Raises ₹26.50 Cr via Warrant Conversion to Promoter Shivalik Rasayan
Medicamen Biotech has approved the allotment of 5,00,000 equity shares upon conversion of warrants to promoter entity Shivalik Rasayan Limited. The shares were issued at ₹530 per share for an aggregate consideration of ₹26.50 crore. This conversion increases the company's paid-up share capital to ₹14.06 crore across 1,40,62,815 equity shares. Notably, the warrant conversion price of ₹530 is at a significant premium to the prevailing market price of ₹252.90, reinforcing promoter financial commitment.
high confidence
What changed5,00,000 warrants converted into 5,00,000 equity shares of face value ₹10 each for promoter entity Shivalik Rasayan.
Why it mattersBrings in ₹26.50 crore in equity funding, boosting net worth and strengthening promoter backing at a premium to the market price.
Total Consideration: Rs. 26,50,00,000/-Issue Price per Share: Rs. 530/-Shares Allotted: 5,00,000Post-allotment Paid-up Capital: Rs. 14,06,28,150/-Fundraise vs Net Worth: ~9.5%
📅 Short termPositive sentiment driver as promoters inject capital at ₹530 per share, well above the current trading price.
📈 Long termStrengthens equity base to support facility modernization and oncology segment ramp-up towards operational breakeven.
⚠ Risk flags
Equity dilution of ~3.56% on expanded capital base
👀 What to Watch
Monitor upcoming shareholding pattern filings to track the exact increase in promoter ownership, alongside cash utilization toward oncology plant scaling.
Medicamen Biotech Q1 Net Profit Up 15% YoY to ₹1.85 Cr; ₹1 Dividend Recommended
Medicamen Biotech reported a consolidated total revenue of ₹48.76 Cr for Q1 FY27, a 12% increase over the ₹43.52 Cr reported in the same quarter last year. Net profit grew 15% YoY to ₹1.85 Cr, although it saw a sharp sequential decline from ₹4.45 Cr in Q4 FY26. The board recommended a final dividend of ₹1.00 per share (10% of face value) for FY26. Notably, the company disclosed paying ₹2.22 lakh in total fines to BSE and NSE for non-compliance regarding the composition of its Nomination and Remuneration Committee.
high confidence
What changedThe company released its Q1 FY27 financial results, declared a final dividend, and disclosed the settlement of regulatory penalties related to board committee composition.
Why it mattersThe results indicate steady year-on-year growth in the core formulations business, but the sequential profit drop and regulatory fines suggest operational and governance areas that require closer monitoring.
Q1 Consolidated Revenue: ₹48.76 CrQ1 Consolidated Net Profit: ₹1.85 CrDividend per share: ₹1.00Total Regulatory Fines: ₹2.22 LakhQ1 Revenue vs FY26 Revenue: 24.6%
📅 Short termThe market may react neutrally as the modest YoY growth is offset by a significant sequential decline in profitability and the disclosure of regulatory non-compliance.
📈 Long termLong-term value depends on the successful scaling of the oncology segment and obtaining US-FDA approvals for high-margin export markets.
👀 What to Watch
Monitor the oncology segment's progress toward its breakeven target and track if the company can stabilize operating margins, which showed significant sequential volatility this quarter.
Medicamen Biotech Reports Zero Deviation in Utilization of ₹53.57 Cr Preferential Issue Funds
Medicamen Biotech Limited has submitted its statement of deviation for the quarter and year ended March 31, 2026, regarding funds raised via a preferential issue. The company raised approximately ₹53.57 crore on April 24, 2025, to fund drug development, capital expenditure, and domestic expansion. As of March 31, 2026, the company has successfully utilized ₹29.30 crore of the total proceeds. The Audit Committee has confirmed that there are no deviations or variations in the utilization of these funds from the objects originally stated.
Key Highlights
Total funds raised through preferential issue on April 24, 2025, amounted to ₹53,56,82,326.93.Cumulative funds utilized for stated objects as of March 31, 2026, stand at ₹29,29,82,326.93.Audit Committee confirmed zero deviation or variation from the original objects of the issue.Funds are being deployed for drug development of 50 SKUs for regulated markets and facility upgrades.
👀 What to Watch
Investors should view this as a positive sign of management's adherence to capital allocation plans. Monitor the progress of the 50 SKU drug development pipeline as the remaining ₹24.27 crore is deployed.
Medicamen Biotech Approves FY26 Results, Recommends ₹1.00 Final Dividend
Medicamen Biotech Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The Board of Directors has recommended a final dividend of ₹1.00 per equity share (10% of face value), subject to shareholder approval. The company also appointed new Cost and Internal Auditors for the 2026-27 fiscal year to strengthen its compliance framework. Importantly, the statutory auditors have issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies.
Key Highlights
Recommended a final dividend of ₹1.00 per equity share of face value ₹10 for the financial year ended March 31, 2026.Statutory auditors M/s Rai Qimat & Associates issued an unmodified opinion on both standalone and consolidated financial results.Appointed M/s SPB & Co as Cost Auditor and M/s Cheena & Associates as Internal Auditor for the financial year 2026-27.The Board meeting commenced at 01:30 PM and concluded at 03:00 PM on May 27, 2026.
👀 What to Watch
Investors should review the detailed profit and loss statements to assess operational growth. The dividend recommendation suggests a stable financial position and commitment to shareholder returns.
Medicamen Biotech Q3 Net Profit Drops 19% to ₹1.63 Cr; Revenue Up Slightly to ₹47 Cr
Medicamen Biotech reported a consolidated net profit of ₹1.63 crore for the quarter ended December 31, 2025, representing a 19.1% decline from ₹2.02 crore in the same quarter last year. Total revenue saw a marginal increase of 2.6% year-on-year, reaching ₹47.04 crore. Despite the quarterly dip, the nine-month performance remains positive with a net profit of ₹5.31 crore compared to ₹4.69 crore in the previous year. The company also announced the cessation of two independent directors following the completion of their tenures.
Key Highlights
Consolidated Total Revenue grew slightly to ₹47.04 crore in Q3 FY26 from ₹45.83 crore in Q3 FY25.Consolidated Net Profit for the quarter fell to ₹1.63 crore, down from ₹2.02 crore in the previous year.Earnings Per Share (EPS) decreased significantly to ₹1.21 from ₹2.30 in the corresponding quarter.Nine-month consolidated net profit showed improvement at ₹5.31 crore versus ₹4.69 crore YoY.Independent Directors Harish Pande and Arun Kumar completed their 10-year tenures effective February 13, 2026.
👀 What to Watch
The quarterly performance indicates margin pressure as profits declined despite stable revenues. Investors should monitor cost management strategies and the impact of board committee reconstitutions on future governance.
Medicamen Biotech Receives EU Approval for Paracetamol Registration in Denmark
Medicamen Biotech Limited has successfully obtained product registration approval for Paracetamol from the Danish Medicine Authority. This approval was secured in collaboration with XGX Pharma, Denmark, marking a significant step into the European Union market. The registration validates the company's adherence to stringent EU manufacturing and quality standards. This development is expected to enhance the company's export capabilities and revenue potential within regulated international markets.
Key Highlights
Received EU approval for Paracetamol product registration from the Danish Medicine Authority.Collaborated with XGX Pharma, Denmark, to facilitate the registration process.Demonstrates compliance with high-level European pharmaceutical regulatory standards.Strengthens the company's presence and growth prospects in the European market.
👀 What to Watch
Investors should view this as a positive regulatory milestone that could drive future export growth. Monitor the company's progress in commercializing this product and seeking further approvals in other EU territories.
⚠️How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI
⚡ Free FlashFinance Newsletters
AI-powered market intelligence in your inbox — completely free. Pick your topics; max 1 email per topic per day. Unsubscribe anytime.
✅ Everything below is 100% free — no payment, no card, ever.
🎉
You're subscribed!
A welcome email with your topics is on its way. Want it even faster? Join us on Telegram or WhatsApp:
